The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Dupilumab reduces local type 2 pro‐inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis
Open accessAbstract
Background: Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a type 2‐mediated inflammatory disease associated with significant clinical, social, and economic burdens and high unmet therapeutic need. Dupilumab, a fully human monoclonal antibody targeting the interleukin‐4 receptor α (IL‐4Rα) subunit, demonstrated efficacy and acceptable safety in CRSwNP and other type 2 diseases (eg, atopic dermatitis and asthma). We now report the local effects of dupilumab on type 2 inflammatory biomarkers in nasal secretions and nasal polyp tissues of patients with CRSwNP in a randomized, placebo‐controlled, phase 2 trial (NCT01920893). Methods: Cytokines, chemokines, and total immunoglobulin E (IgE) levels were measured using immunoassay techniques in nasal secretions and nasal polyp tissue homogenates of CRSwNP patients receiving dupilumab 300 mg or placebo weekly for 16 weeks. Results: With dupilumab, type 2 biomarker concentrations decreased in nasal secretions (least squares mean area under the curve from 0 to 16 weeks for the change from baseline) vs placebo for eotaxin‐3 (−30.06 vs −0.86 pg/mL; P = 0.0008) and total IgE (−7.90 vs −1.86 IU/mL; P = 0.022). Dupilumab treatment also decreased type 2 biomarker levels in nasal polyp tissues at Week 16 vs baseline for eosinophilic cationic protein (P = 0.008), eotaxin‐2 (P = 0.008), eotaxin‐3 (P = 0.031), pulmonary and activation‐regulated chemokine (P = 0.016), IgE (P = 0.023), and IL‐13 (P = 0.031). Conclusions: Dupilumab treatment reduced multiple biomarkers of type 2 inflammation in nasal secretions and polyp tissues of patients with CRSwNP, demonstrating that antagonism of IL‐4Rα signaling suppresses IL‐4‐/IL‐13‐dependent processes, such as mucosal IgE formation, as well as the expression of chemokines attracting inflammatory cells to the nasal mucosa.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fokkens, W. J., Lund, V. J., Mullol, J., Bachert, C., Alobid, I., Baroody, F., Cohen, N., Cervin, A., Douglas, R., Gevaert, P., et al. (2012) · Rhinology journal · doi:10.4193/rhino12.000 · Cited by 2,387
Self-citationTwo Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Self-citationThe cytokine network in asthma and chronic obstructive pulmonary disease
Barnes, P. J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36130 · Cited by 982 · cited 2×
“In contrast, IL‐13 is thought to have a greater role in stimulating mucus hypersecretion, airway hyperresponsiveness and subepithelial fibrosis, and secretion of chemokines such as eotaxins.(21) Both IL‐4 and IL‐13 induce secretion of thymus and activation‐regulated chemokine (TARC) and pulmonary and activation‐regula…”
BackgroundBachert, C., Mannent, L., Naclerio, R. M., Mullol, J., Ferguson, B. J., Gevaert, P., Hellings, P., Jiao, L., Wang, L., Evans, R. R., et al. (2016) · JAMA · doi:10.1001/jama.2015.19330 · Cited by 794
Self-citationTargeting key proximal drivers of type 2 inflammation in disease
Gandhi, N. A., Bennett, B. L., Graham, N. M. H., Pirozzi, G., Stahl, N., & Yancopoulos, G. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd4624 · Cited by 766
Self-citationMepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis
Gevaert, P., Van Bruaene, N., Cattaert, T., Van Steen, K., Van Zele, T., Acke, F., De Ruyck, N., Blomme, K., Sousa, A. R., Marshall, R. P., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.07.056 · Cited by 629
Self-citation
Cited by
Harb, H., & Chatila, T. A. (2020) · Clinical & Experimental Allergy · doi:10.1111/cea.13491 · Cited by 518
Role of IL‐25, IL‐33, and TSLP in triggering united airway diseases toward type 2 inflammation
Hong, H., Liao, S., Chen, F., Yang, Q., & Wang, D. (2020) · Allergy · doi:10.1111/all.14526 · Cited by 272
Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases
Hamilton, J. D., Harel, S., Swanson, B. N., Brian, W., Chen, Z., Rice, M. S., Amin, N., Ardeleanu, M., Radin, A., Shumel, B., et al. (2021) · Clinical & Experimental Allergy · doi:10.1111/cea.13954 · Cited by 192
Self-citationAdvances and novel developments in mechanisms of allergic inflammation
Han, X., Krempski, J. W., & Nadeau, K. (2020) · Allergy · doi:10.1111/all.14632 · Cited by 129
Metadata
- Authors
- Jonstam, K., Swanson, B. N., Mannent, L. P., Cardell, L., Tian, N., Wang, Y., Zhang, D., Fan, C., Holtappels, G., Hamilton, J. D., Grabher, A., Graham, N. M. H., Pirozzi, G., & Bachert, C.
- Venue
- Allergy
- Publisher
- Wiley
- Published
- 2019-01-21
- Volume
- 74
- Issue
- 4
- Pages
- 743-752
- ISSN
- 0105-4538 (ISSN-L)
- 1398-9995
- OpenAlex
- W2902877715
- Cited by
- 181
- References
- 6
- FWCI
- 16.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dupilumab reduces local type 2 pro‐inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis. https://app.cochat.ai/papers/10.1111/all.13685
- The paper
- Jonstam, K., Swanson, B. N., Mannent, L. P., Cardell, L., Tian, N., Wang, Y., Zhang, D., Fan, C., Holtappels, G., Hamilton, J. D., Grabher, A., Graham, N. M. H., Pirozzi, G., & Bachert, C. (2019). Dupilumab reduces local type 2 pro‐inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis. Allergy. https://doi.org/10.1111/all.13685
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.